Sen. Collins Questions FDA Official on Whether Medicare Overstepped in Restricting Alzheimer's Treatments
April 28, 2022
April 28, 2022
WASHINGTON, April 28 -- Sen. Susan M. Collins, R-Maine, issued the following news release:
At a hearing focused on the Food and Drug Administration (FDA), U.S. Senator Susan Collins (R-ME), a member of the Senate Health Committee and a founder and co-chair of the Congressional Task Force on Alzheimer's Disease, questioned Dr. Patrizia Cavazzoni, the Director of the Center for Drug Evaluation and Research at FDA, about the Centers for Medicare and Medicaid Services' (CMS) d . . .
At a hearing focused on the Food and Drug Administration (FDA), U.S. Senator Susan Collins (R-ME), a member of the Senate Health Committee and a founder and co-chair of the Congressional Task Force on Alzheimer's Disease, questioned Dr. Patrizia Cavazzoni, the Director of the Center for Drug Evaluation and Research at FDA, about the Centers for Medicare and Medicaid Services' (CMS) d . . .